Lloyd-Jones, Donald M <br/><br/>
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?  [electronic resource] 

 -  JAMA cardiology  09 2017 
 - 937-938 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2380-6591 
<br/><br/><label>Standard No.: </label>10.1001/jamacardio.2017.2288  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--therapeutic use<br/>Atherosclerosis--blood<br/>Cholesterol, LDL--blood<br/>Drug Therapy, Combination<br/>Ezetimibe--therapeutic use<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Hypercholesterolemia--blood<br/>PCSK9 Inhibitors<br/>Patient Selection<br/>RNA, Small Interfering--therapeutic use<br/>Risk Reduction Behavior